Pfizer Stock: The Reversal Should Keep Going


  • Pfizer’s stock initially showed signs of recovery, but then stagnated while the rest of the market continued to grow. However, I expect a recovery in the medium term.
  • The Company’s Q1 results showed strong performance in non-COVID products and cost-saving measures, leading to analyst sentiment improvement.
  • The recent Wall Street earnings estimates indicate that the Street expects PFE to bottom out in FY2024 in terms of EPS and that fundamentals will then rebound.
  • Despite risks like patent expirations, Pfizer’s undervaluation by at least 36.7% and growth opportunities make it a good long-term investment.
  • The reversal should keep going, hence my “Strong Buy” rating.



Into & Thesis

I reinitiated my coverage of Pfizer Inc. (NYSE:PFE) stock at the end of December 2023. Since then, I have published only two articles, which, unfortunately, haven’t proven effective in terms of performance: PFE’s total return has remained stagnant, hovering around

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in PFE over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Hold On! Can’t find the equity research you’ve been looking for?

Now you can get access to the latest and highest-quality analysis of recent Wall Street buying and selling ideas with just one subscription to Beyond the Wall Investing! There is a free trial and a special discount of 10% for you. Join us today!

Leave a Reply

Your email address will not be published. Required fields are marked *